Genmab — December 2019
-
Netop.
-
-
The results are in! The majority of voters (45%) thought CAR T trials were the highlight of #ASH19, closely followed by novel agents for RRMM (37%). The MM Hub will be bringing you written coverage from key sessions very soon! Keep checking back & follow @MM_Hub
! https://twitter.com/MM_Hub/status/1205192776910024707 -
Forståeligt at forskere synes det er interessant. Fra et kommercielt synspunkt er vi Genmab investorer beroliget i og med at teknologien ikke ser ud til at være parat til de første linier i behandlingen. Men for patienter er det en ny mulighed med lidt mere risiko i - men alternativet er værre.
-
-
Solsen...Hvordan kommer du dog på den tanke.
-
Mon ham her endelig har fundet fejlen i regnearket https://finance.yahoo.com/news/bristol-myers-business-development-head-180610443.html
-
God morgen
-
God morgen.
-
I anledning af de seneste dags fald: https://www.proinvestor.com/index.php?p=debat_1&postid=80119
-
Godmorgen, kan dette være årsagen til de seneste dags fald ?https://seekingalpha.com/news/3526005-house-passes-drug-pricing-bill-senate-unlikely-to-support?utm_medium=email&utm_source=seeking_alpha
-
Det tror jeg ikke. Vi så ikke store fald andre steder i sektoren.
-
The Anti-CD38 Antibody Therapy in Multiple Myeloma https://www.mdpi.com/2073-4409/8/12/1629
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind